Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

ABBVIE CALL CENTER 844-663-3742
abbvieclinicaltrials@abbvie.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Back

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting

Open to: FEMALE

Age: 18.0 - N/A

Cheltenham London London Northwood Southampton Sutton Manchester Swansea

Medical Conditions

Fallopian Tube Neoplasms
Peritoneal Neoplasms
Hypersensitivity

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2022 Apr 2029

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks

Intervention Arm Group : Arm 1;

Intervention Type : DRUG
Intervention Description : Participants will receive Bevacizumab 15mg/kg every 3 weeks

Intervention Arm Group : Arm 2;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Cheltenham General Hospital /ID# 269427
    Cheltenham
    Gloucestershire
    GL53 7AN
  • Guy's Hospital /ID# 269426
    London
    Greater London
    SE1 9RT
  • The Royal Marsden - Chelsea /ID# 269102
    London
    Greater London
    SW3 6JJ
  • Mount Vernon Hospital /ID# 269423
    Northwood
    Greater London
    HA6 2RN
  • University Hospital Southampton /ID# 269425
    Southampton
    Hampshire
    SO16 6YD
  • The Royal Marsden - Sutton /ID# 269103
    Sutton
    Surrey
    SM2 5PT
  • The Christie /ID# 269428
    Manchester
    M20 4BX
  • Singleton Hospital /ID# 269424
    Swansea
    SA2 8QA

ABBVIE CALL CENTER 844-663-3742
abbvieclinicaltrials@abbvie.com



The study is sponsored by AbbVie and is in collaboration with GOG Foundation.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05445778
Last updated 17 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top